Literature DB >> 30560748

Patient isolation for infection control and patient experience.

Zishan K Siddiqui1, Sarah Johnson Conway1, Mohammed Abusamaan1, Amanda Bertram1, Stephen A Berry2, Lisa Allen3, Ariella Apfel1, Holley Farley4, Junya Zhu5, Albert W Wu1, Daniel J Brotman1.   

Abstract

OBJECTIVE: Hospitalized patients placed in isolation due to a carrier state or infection with resistant or highly communicable organisms report higher rates of anxiety and loneliness and have fewer physician encounters, room entries, and vital sign records. We hypothesized that isolation status might adversely impact patient experience as reported through Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) surveys, particularly regarding communication.
DESIGN: Retrospective analysis of HCAHPS survey results over 5 years.
SETTING: A 1,165-bed, tertiary-care, academic medical center.PatientsPatients on any type of isolation for at least 50% of their stay were the exposure group. Those never in isolation served as controls.
METHODS: Multivariable logistic regression, adjusting for age, race, gender, payer, severity of illness, length of stay and clinical service were used to examine associations between isolation status and "top-box" experience scores. Dose response to increasing percentage of days in isolation was also analyzed.
RESULTS: Patients in isolation reported worse experience, primarily with staff responsiveness (help toileting 63% vs 51%; adjusted odds ratio [aOR], 0.77; P = .0009) and overall care (rate hospital 80% vs 73%; aOR, 0.78; P < .0001), but they reported similar experience in other domains. No dose-response effect was observed.
CONCLUSION: Isolated patients do not report adverse experience for most aspects of provider communication regarded to be among the most important elements for safety and quality of care. However, patients in isolation had worse experiences with staff responsiveness for time-sensitive needs. The absence of a dose-response effect suggests that isolation status may be a marker for other factors, such as illness severity. Regardless, hospitals should emphasize timely staff response for this population.

Entities:  

Year:  2018        PMID: 30560748     DOI: 10.1017/ice.2018.324

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Patient care experience with utilization of isolation precautions: systematic literature review and meta-analysis.

Authors:  R Nair; E N Perencevich; M Goto; D J Livorsi; E Balkenende; E Kiscaden; M L Schweizer
Journal:  Clin Microbiol Infect       Date:  2020-01-30       Impact factor: 8.067

2.  Nursing Workflow Change in a COVID-19 Inpatient Unit Following the Deployment of Inpatient Telehealth: Observational Study Using a Real-Time Locating System.

Authors:  Stacie Vilendrer; Mary E Lough; Donn W Garvert; Monique H Lambert; Jonathan Hsijing Lu; Birju Patel; Nigam H Shah; Michelle Y Williams; Samantha M R Kling
Journal:  J Med Internet Res       Date:  2022-06-17       Impact factor: 7.076

3.  Patient Perspectives of Inpatient Telemedicine During the COVID-19 Pandemic: Qualitative Assessment.

Authors:  Stacie Vilendrer; Sarah Sackeyfio; Eliel Akinbami; Roy Ghosh; Jacklyn Ha Luu; Divya Pathak; Masahiro Shimada; Emmanuelle Elise Williamson; Lisa Shieh
Journal:  JMIR Form Res       Date:  2022-03-30

4.  Experiences of COVID-19 patients in a Fangcang shelter hospital in China during the first wave of the COVID-19 pandemic: a qualitative descriptive study.

Authors:  Yaping Zhong; Huan Zhao; Tsorng-Yeh Lee; Tianchi Yu; Ming Fang Liu; Ji Ji
Journal:  BMJ Open       Date:  2022-09-14       Impact factor: 3.006

5.  SARS-CoV-2 infection and COVID-19: The lived experience and perceptions of patients in isolation and care in an Australian healthcare setting.

Authors:  Ramon Z Shaban; Shizar Nahidi; Cristina Sotomayor-Castillo; Cecilia Li; Nicole Gilroy; Matthew V N O'Sullivan; Tania C Sorrell; Elizabeth White; Kate Hackett; Shopna Bag
Journal:  Am J Infect Control       Date:  2020-09-02       Impact factor: 2.918

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.